| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial intelligence (AI) | n/a | n/a |
| Intrinsic value (DCF) | n/a | |
| Graham-Dodd Method | n/a | |
| Graham Formula | n/a |
Skye Bioscience, Inc. (OTC: SKYE) is a clinical-stage biopharmaceutical company pioneering cannabinoid-based therapeutics for ocular and systemic diseases. Headquartered in San Diego, California, the company focuses on developing novel cannabinoid-derived molecules, with its lead candidate, SBI-100, in Phase I trials for glaucoma and ocular hypertension. Skye is also advancing SBI-200, a preclinical asset targeting uveitis, dry eye syndrome, macular degeneration, and diabetic retinopathy. Formerly known as Emerald Bioscience, Inc., the company rebranded in 2021 to reflect its refined focus on leveraging cannabinoid science for unmet medical needs. Operating in the high-growth biotechnology sector, Skye Bioscience aims to capitalize on the expanding market for cannabinoid-based therapies, projected to exceed $50 billion by 2030. With no current revenue but a strong cash position, the company is strategically positioned to advance its pipeline through key clinical milestones.
Skye Bioscience presents a high-risk, high-reward opportunity for investors with a tolerance for clinical-stage biotech volatility. The company’s focus on cannabinoid-based ophthalmology therapies addresses a niche but growing market, with glaucoma alone affecting over 80 million globally. A robust cash position (~$68.4M) provides runway for near-term development, but the lack of revenue and negative EPS (-$0.73) underscore dependence on trial success. The 1.75 beta indicates heightened sensitivity to market swings, while the OTC listing adds liquidity risk. Key catalysts include Phase I data for SBI-100 and preclinical progress for SBI-200. Competition from established glaucoma players and regulatory hurdles for cannabinoid drugs remain material risks.
Skye Bioscience’s competitive edge lies in its specialized focus on cannabinoid pharmacology for ocular diseases—a space with limited targeted players. Unlike broad-spectrum cannabinoid companies, Skye’s SBI-100 and SBI-200 are designed to harness specific cannabinoid receptor modulation, potentially offering efficacy without psychoactive effects. This differentiation is critical in ophthalmology, where precision therapeutics are valued. However, the company faces significant challenges: (1) competing against entrenched glaucoma treatments like prostaglandin analogs (e.g., Latanoprost generics), (2) competing with larger biotechs with deeper pipelines (e.g., Regeneron’s Eylea for retinal diseases), and (3) navigating the regulatory complexities of cannabinoid-based drugs. Skye’s preclinical assets also enter crowded markets (e.g., dry eye has over 20 approved therapies). The company’s success hinges on demonstrating superior safety/tolerability versus existing options and securing intellectual property around its formulations. Early-mover advantage in cannabinoid ophthalmology could be offset by slower adoption in conservative medical communities.